Strategy
MSTR
Meta Platforms
META
Oracle
ORCL
Amazon
AMZN
Salesforce
CRM
US Stock MarketDetailed Quotes
SLRN Acelyrin
- 2.600
- +0.030+1.17%
Close Feb 26 16:00 ET
- 2.590
- -0.010-0.38%
Post 19:21 ET
260.85MMarket Cap-0.98P/E (TTM)
2.650High2.540Low2.40MVolume2.580Open2.570Pre Close6.26MTurnover3.98%Turnover RatioLossP/E (Static)100.33MShares8.76052wk High0.49P/B156.58MFloat Cap1.84552wk Low--Dividend TTM60.22MShs Float29.880Historical High--Div YieldTTM4.27%Amplitude1.845Historical Low2.607Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Acelyrin Stock Forum
share buyback at $3, shorts only touched this a tiny bit. I think shorts would only touch this once it got over $3.
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
Thursday, 20th February at 9:00 pm
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital...
$Acelyrin (SLRN.US)$
has options
nfa
$Acelyrin (SLRN.US)$
has options
nfa
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
Based on the provided information, Alumis Inc. (ALMS) and ACELYRIN, Inc. (SLRN) have announced a merger agreement. In this all-stock transaction, ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock they own. Post-merger, Alumis stockholders will own approximately 55% of the combined company, while ACELYRIN stockholders will own about 45% on a fully diluted basis. 
Estimating the Post-Merger Stock Price of Alu...
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-Mediated Diseases
No comment yet